X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azd2281 (34) 34
index medicus (27) 27
humans (26) 26
olaparib (22) 22
oncology (20) 20
tumors (19) 19
female (17) 17
poly polymerase (16) 16
pharmacology & pharmacy (13) 13
animals (12) 12
cancer (12) 12
maintenance therapy (10) 10
inhibition (9) 9
middle aged (9) 9
phthalazines - therapeutic use (9) 9
piperazines - therapeutic use (9) 9
poly polymerase inhibitors - pharmacology (9) 9
adult (8) 8
aged (8) 8
breast cancer (8) 8
medicine & public health (8) 8
mutation (8) 8
parp inhibitor (8) 8
phthalazines - pharmacology (8) 8
piperazines - pharmacology (8) 8
poly polymerase inhibitors (8) 8
therapy (8) 8
antineoplastic agents - pharmacology (7) 7
ovarian neoplasms - drug therapy (7) 7
pharmacology/toxicology (7) 7
repair (7) 7
safety (7) 7
sensitivity (7) 7
antineoplastic agents - therapeutic use (6) 6
breast neoplasms - drug therapy (6) 6
cell line, tumor (6) 6
cell proliferation - drug effects (6) 6
chemotherapy (6) 6
combination (6) 6
mice (6) 6
monosaccharides (6) 6
neoplasms - drug therapy (6) 6
ovarian cancer (6) 6
ovarian-cancer (6) 6
pharmacokinetics (6) 6
phthalazines - administration & dosage (6) 6
phthalazines - adverse effects (6) 6
piperazines - administration & dosage (6) 6
piperazines - adverse effects (6) 6
poly polymerase-1 (6) 6
polymerase (6) 6
sugars (6) 6
dna-repair (5) 5
drug therapy (5) 5
male (5) 5
open-label (5) 5
ovarian neoplasms - pathology (5) 5
analysis (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
bevacizumab (4) 4
brca1 (4) 4
brca1 protein (4) 4
breast-cancer (4) 4
care and treatment (4) 4
cisplatin (4) 4
dna repair (4) 4
dose-response relationship, drug (4) 4
enzyme inhibitors - pharmacology (4) 4
growth (4) 4
health aspects (4) 4
internal medicine (4) 4
mutant-cells (4) 4
ovarian neoplasms - genetics (4) 4
parp (4) 4
parp inhibitors (4) 4
phthalazines - pharmacokinetics (4) 4
piperazines - pharmacokinetics (4) 4
poly (4) 4
poly polymerase inhibitors - administration & dosage (4) 4
poly polymerases - metabolism (4) 4
synthetic lethality (4) 4
toxicology (4) 4
treatment outcome (4) 4
administration, oral (3) 3
adp (3) 3
aged, 80 and over (3) 3
antineoplastic agents - chemistry (3) 3
article (3) 3
brca1 protein - genetics (3) 3
breast (3) 3
cancer research (3) 3
cancer therapies (3) 3
clinical trials (3) 3
dosage and administration (3) 3
double-blind (3) 3
enzymes (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 245 - 251
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 15, pp. 1382 - 1392
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 5/2019, Volume 58, Issue 5, pp. 615 - 625
Olaparib is a first-in-class potent oral poly(ADP-ribose) polymerase inhibitor.The aims of this analysis were to establish an integrated population... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | RECURRENT | SAFETY | POLYMERASE | PHARMACOLOGY & PHARMACY | AZD2281 | JAPANESE PATIENTS | INHIBITOR | TUMORS | MAINTENANCE THERAPY | FOOD
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 07/2015, Volume 13, Issue 1, p. 225
Background: An important portion of asthmatics do not respond to current therapies. Thus, the need for new therapeutic drugs is urgent. We have demonstrated a... 
Olaparib (AZD2281) | Th2 cytokines | Allergen-induced eosinophilia | Allergen-specific IgE | Adoptive transfer | PARP inhibition | MEDICINE, RESEARCH & EXPERIMENTAL | POLY(ADP-RIBOSE) POLYMERASE INHIBITION | ALLERGIC AIRWAY INFLAMMATION | OVARIAN-CANCER | MAINTENANCE THERAPY | NEGATIVE BREAST-CANCER | MURINE MODEL | BRCA | NF-KAPPA-B | EXPRESSION | LUNG INFLAMMATION | GATA3 Transcription Factor - genetics | Spleen - immunology | Bronchial Hyperreactivity - immunology | Ovalbumin - immunology | Bronchial Hyperreactivity - drug therapy | Humans | Immunoglobulin E - biosynthesis | Adoptive Transfer | Th2 Cells - drug effects | Antigens, CD - metabolism | CD4-Positive T-Lymphocytes - immunology | Th1 Cells - metabolism | Asthma - immunology | Mucus - metabolism | Eosinophilia - drug therapy | GATA3 Transcription Factor - metabolism | Disease Models, Animal | Th1 Cells - drug effects | Cytokines - metabolism | Mice, Inbred C57BL | Piperazines - therapeutic use | Gene Knockout Techniques | Asthma - drug therapy | Bronchial Hyperreactivity - complications | Piperazines - pharmacology | T-Box Domain Proteins - genetics | Th2 Cells - metabolism | T-Box Domain Proteins - metabolism | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Animals | Eosinophilia - immunology | Asthma - complications | Eosinophilia - complications | CD4-Positive T-Lymphocytes - drug effects | Allergens | Genes | Immunoglobulin E | Albumin | Genetic research | Inflammation | B cells | T cells | Asthma
Journal Article
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN 0344-5704, 10/2016, Volume 78, Issue 4, pp. 775 - 784
Background Some therapeutic agents in oncology can be causally associated with specific cardiovascular events including QT/QT(c) interval prolongation. We... 
QT interval | SENSITIVITY | Olaparib | PHASE-2 | OVARIAN-CANCER | MAINTENANCE THERAPY | Heart rate | Cardiac repolarization | Phase I | QT(c) interval | PHARMACOKINETICS | ONCOLOGY | PHARMACOLOGY & PHARMACY | AZD2281 | Safety | FOOD
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2012, Volume 106, Issue 3, pp. 468 - 474
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 50, pp. 87638 - 87646
Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer... 
Hypoxia | Olaparib | Radiotherapy | Targeted therapy | Neoadjuvant treatment | targeted therapy | hypoxia | POLY(ADP-RIBOSE) POLYMERASE | CELLS | TUMORS | neoadjuvant treatment | CELL BIOLOGY | REPAIR | RADIOSENSITIZATION | olaparib | PARP INHIBITION | radiotherapy | AZD2281
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 2, pp. 514 - 522
Journal Article